The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus
The design and synthesis of RFI-641, a new potent and selective inhibitor of the respiratory syncytial virus, both in vitro and in vivo, are described.
Section snippets
Acknowledgements
This paper is dedicated to the memory of Dr. Yakov Gluzman. The authors wish to thank Drs Stanley Lang, Tarek Mansour, Brian O'Hara, John O'Connell, Anna Gazumyan and George Ellestad for valuable discussions, Dr. Boris Feld for providing the assay data and Mr. Sanford Strunk for scale-up of RFI-641.
References (16)
- et al.
Antiviral Res.
(1997) - et al.
Antiviral Res.
(1999) Seminars in Respiratory and Critical Care Medicine
(2000)- Hall, C. B.; McCarthy, C. A. In Principles and Practice of Infectious Diseases, 5th ed.; Mandell, G. L., Bennett, J....
- Hall, C. B. Presented at the Symposium RSV after 43 years, Hutchinson Island in Stuart, FL, 8–11 November...
- et al.
Curr. Pharm. Des
(2000) Int. J. Antimicrob. Agents
(1996)- et al.
J. Nat. Prod.
(1998)
Cited by (39)
Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities
2022, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :Nasal administration of liposomal poly ICLC in mice before or shortly after influenza infection has shown inhibition of viral replication, providing a significant reduction in pulmonary viral titres and a higher survival rate of infected mice [121]. Intranasal administration of antiviral agents like CL-387626 [122], RF-641 [122–124], JNJ-2408068 [125–129] and AS-1411 [130] have shown good antiviral activity in various animal models for RSV infection. Poly ICLC [131,132], ALX0171 [133], ALN-RSV01 [134], and MDT-637 [135–137] were also studied in human subjects for their effectiveness against respiratory viral infections as shown in Table 2.
Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery
2017, Biochemical PharmacologyCitation Excerpt :The first trial is a Phase 1b study in which also the potential anti-viral effect of single dose of AK0529 will be studied in infants hospitalized with an RSV infection, the second trial is a phase 2 study. RFI-641 (Pfizer) is a small dendrimer-like compound with potent in vitro activity against both RSV-A and RSV-B laboratory strains and clinical isolates (EC50 values around 20 nM) [73]. The compound was shown to inhibit binding as well as fusion of RSV with cells and showed to be resistant to viruses showing a mutation at position 446 of the F-protein (Fig. 2A) [74,75].
Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead
2015, Advanced Drug Delivery ReviewsCitation Excerpt :RFI-641 (Fig. 2) from Wyeth-Ayerst is a potent analog of their original lead compound CL-387626 [230]. RFI-641 showed good efficacy following intranasal administration in mouse and African green monkey models of RSV infection at doses as low as 0.04 mg/kg [230–232]. VP-14637 (Fig. 2; syn.
Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo
2006, Bioorganic and Medicinal Chemistry LettersDevelopment of Antivirals against Respiratory Syncytial Virus
2006, Perspectives in Medical VirologyPyrimidine containing RSV fusion inhibitors
2005, Bioorganic and Medicinal Chemistry Letters